<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530893</url>
  </required_header>
  <id_info>
    <org_study_id>FASTCHECK</org_study_id>
    <nct_id>NCT01530893</nct_id>
  </id_info>
  <brief_title>Flavonoids, Blood Pressure and Blood Vessel Function</brief_title>
  <acronym>FASTCHECK</acronym>
  <official_title>Are the Cardiovascular Responses of Individuals at Mild to Moderate Cardiovascular Risk Influenced by Dietary Flavonoid Sub-class and Dietary Form?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of East Anglia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this placebo-controlled study is to determine whether flavonoids&#xD;
      beneficially affect markers of cardiovascular disease risk in healthy subjects at elevated&#xD;
      cardiovascular risk.&#xD;
&#xD;
      The underlying mechanisms of action of flavonoids will be assessed on blood biomarkers and we&#xD;
      will assess the effects of the food matrix, and aspects of isoflavone metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will be healthy males (aged 50-75 years) at elevated risk of&#xD;
      cardiovascular (CV) disease.&#xD;
&#xD;
      A target of 60 participants will be required to complete the study and a total of 70 subjects&#xD;
      will be targeted (n=70 subjects * ~85% anticipated completion rate = 60 subjects to complete&#xD;
      the study).&#xD;
&#xD;
      This placebo-controlled study will test the relative efficacy of 4 different flavonoid&#xD;
      sub-classes ((i) flavan-3-ol, (ii) anthocyanin, (iii) flavanone and (iv) isoflavone).&#xD;
&#xD;
      Accordingly, subjects will be randomised to one of the four flavonoid study groups ((i) to&#xD;
      (iv) outlined above), and then will consume each of the following treatments in random order:&#xD;
&#xD;
        1. dietary flavonoid + placebo supplement&#xD;
&#xD;
        2. placebo food + commercially available/produced flavonoid supplement&#xD;
&#xD;
        3. placebo food + placebo supplement&#xD;
&#xD;
      Additionally, an isoflavone metabolite will be fed to establish potential vascular effects.&#xD;
&#xD;
      Each sub-class will be assessed separately and a 1 week wash-out period between treatments&#xD;
      will be observed.&#xD;
&#xD;
      At each assessment visit, vascular function will be assessed pre- and post-intervention, with&#xD;
      subsequent assessments made to coincide with anticipated peak plasma concentrations.&#xD;
&#xD;
      Dietary intake will be monitored during the study and participants will be required to adhere&#xD;
      to a range of dietary and lifestyle restrictions within 3 days of each assessment to reduce&#xD;
      potential confounding of the data assessment of interest.&#xD;
&#xD;
      A standard battery of vascular function tests will be performed on all intervention groups,&#xD;
      with each assessment visit performed in an identical manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in blood vessel control (pressure and endothelial function) at time points coinciding with postprandial [anticipated] peak plasma flavonoid concentration.</measure>
    <time_frame>acute postprandial; up to 24 hours, dependent on flavonoid sub-classification studied</time_frame>
    <description>Assessment of vascular function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in effects of flavonoids introduced by food matrix</measure>
    <time_frame>acute postprandial; up to 24 hours dependent on flavonoid sub-classification studied</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Cardiovascular Disease Risk Reduction</condition>
  <arm_group>
    <arm_group_label>Intervention group A: flavanones</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group B: isoflavones</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group C: Flavan-3-ols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group D: Anthocyanins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanone - supplement</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group A: flavanones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flavanone - food</intervention_name>
    <description>acute single dose</description>
    <arm_group_label>Intervention group A: flavanones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flavanone - placebo</intervention_name>
    <description>acute single dose (flavanone free)</description>
    <arm_group_label>Intervention group A: flavanones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoflavone - supplement</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group B: isoflavones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoflavone - food</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group B: isoflavones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoflavone - placebo</intervention_name>
    <description>acute single dose (isoflavone free)</description>
    <arm_group_label>Intervention group B: isoflavones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoflavone - metabolite supplement</intervention_name>
    <description>acute single optimal dose of commercial product</description>
    <arm_group_label>Intervention group B: isoflavones</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavan-3-ol - supplement</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group C: Flavan-3-ols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flavan-3-ol - food</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group C: Flavan-3-ols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flavan-3-ol - placebo</intervention_name>
    <description>acute single dose (flavan-3-ol free)</description>
    <arm_group_label>Intervention group C: Flavan-3-ols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anthocyanin - supplement</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group D: Anthocyanins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anthocyanin - food</intervention_name>
    <description>acute single optimal dose</description>
    <arm_group_label>Intervention group D: Anthocyanins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anthocyanin - placebo</intervention_name>
    <description>acute single dose (anthocyanin free)</description>
    <arm_group_label>Intervention group D: Anthocyanins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  50 to 75 years old&#xD;
&#xD;
          -  At elevated risk of CV disease&#xD;
&#xD;
          -  Screening blood pressure of &lt; 160/90mmHg (at rest)&#xD;
&#xD;
          -  Successful biochemical, haematological and urinalysis assessment at screening (as&#xD;
             judged by clinical advisor)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smokers, or ex-smokers ceasing &lt; 3 months ago&#xD;
&#xD;
          -  Subjects with existing or significant past medical history of vascular disease or&#xD;
             medical conditions likely to affect the study measures (as judged by clinical advisor)&#xD;
&#xD;
          -  Those with known allergies to the intervention treatments&#xD;
&#xD;
          -  Those unprepared to adhere to dietary restrictions during the trial&#xD;
&#xD;
          -  Parallel participation in another research project which involves concurrent dietary&#xD;
             intervention and/or sampling of biological fluids/material&#xD;
&#xD;
          -  Having vaccinations (excluding the flu vaccination) or antibiotics within 3 months of&#xD;
             start of trial, and those with vaccinations scheduled for during the trial&#xD;
&#xD;
          -  Taking flavonoid containing food / dietary supplements likely to affect the study&#xD;
             results&#xD;
&#xD;
          -  Prescribed lipid lowering, hypertension, vasodilators (e.g. Viagra) or antibiotic&#xD;
             medication&#xD;
&#xD;
          -  Unsatisfactory biochemical, haematological or urinary assessment at screening,&#xD;
             indicating abnormal; renal or liver function, full blood profile, impaired glucose&#xD;
             handling, deranged lipids or measurements considered to be counter indicative of the&#xD;
             study by the clinical advisor&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aedin Cassidy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of East Anglia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition, Norwich Medical School</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flavonoids</keyword>
  <keyword>vascular function</keyword>
  <keyword>randomised controlled trial</keyword>
  <keyword>placebo controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

